Cyclerion and Korsana Merge to Form Alzheimer's-Focused Biotech Powerhouse

Cyclerion Therapeutics has agreed to merge with Korsana Biosciences, sending its share price soaring. The deal will create a new company focused on Alzheimer's research, with existing Cyclerion investors holding just a small stake in the combined business. The merger also includes a major funding round to support future drug development. The merger will see Korsana's CEO, Jonathan Violin, take charge of the new organisation. Tomas Kiselak from Fairmount will serve as chairman. Under the terms, Cyclerion's current shareholders will own only 1.5% of the combined company, while Korsana's backers will control 98.5%.

The transaction includes a $380 million private investment round, led by Fairmount and Venrock Healthcare Capital Partners. This capital is expected to fund operations until at least 2029, giving the company time to advance its clinical programs. Korsana's lead drug, KRSA-028 for Alzheimer's, remains in early testing, with no human efficacy results anticipated before late 2027. Cyclerion's existing programs, such as CYC-126 for treatment-resistant depression, are likely to be sidelined under the new structure. The combined entity will rebrand as Korsana Biosciences and trade on Nasdaq under the ticker 'KRSA'. Cyclerion's most recent financial report showed $2.07 million in revenue but a net loss of $3.53 million. Korsana went public in March 2024, and its stock has seen sharp swings, trading between $1.03 and $3.79 over the past year. Following the merger announcement, shares surged, with daily prices ranging from $5.37 to $8.48 on heavy volume of 240 million shares. The company currently lacks Wall Street analyst coverage, leaving investors without independent research on its prospects.

The deal provides Korsana with significant funding to push its Alzheimer's research forward. Cyclerion's legacy programs will take a back seat as the new leadership focuses on the combined pipeline. The merged company now has a multi-year financial runway, though key drug data remains years away.